Health ICI/TKI Combo Maintains Survival Benefit in Advanced RCC Eli Pacheco Feb 21, 2023 0 SAN FRANCISCO -- First-line nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to demonstrate clinically meaningful…